Match!
Derek J. Jonker
Ottawa Hospital Research Institute
CancerPathologyOncologyColorectal cancerMedicine
201Publications
25H-index
6,793Citations
What is this?
Publications 237
Newest
#1David J. Stewart (U of O: University of Ottawa)H-Index: 52
#2Dominick Bossé (U of O: University of Ottawa)H-Index: 9
Last. Michael Fung-Kee-Fung (U of O: University of Ottawa)H-Index: 19
view all 6 authors...
Abstract Progression-free survival (PFS) hazard ratios and gain in median PFS are suggested predictors of overall survival (OS) gain (with gain defined as experimental arm minus control arm values). We assessed use of half-lives (time to progression/death of half remaining patients). We reviewed randomized trials from Journal of Clinical Oncology and New England Journal of Medicine, 01/2012-06/12/2017 (discovery series) and 01/01/2007-12/31/2011 (first validation series). If PFS or OS gains were...
Source
#1John Hilton (Ottawa Hospital)H-Index: 6
#2K GelmonH-Index: 72
Last. John SoongH-Index: 2
view all 16 authors...
Background: G-quadruplexes are secondary DNA structures that reversibly form in guanine-rich regions within DNA. Our group has demonstrated that CX-5461 selectively binds and stabilizes G-quadruplex structures, causing replication fork collapse and double-stranded DNA breaks. In BRCA1/2 deficient cell lines and xenograft models, synthetic lethality was observed. We are conducting a phase I study of CX-5461, a first-in-class G-quadruplex stabilizer, in patients with advanced solid tumors enrichin...
Source
#1H-J Lenz (SC: University of Southern California)H-Index: 79
#2Peter GibbsH-Index: 45
Last. Aimery de GramontH-Index: 42
view all 11 authors...
Source
#1Nirit Yarom (TAU: Tel Aviv University)H-Index: 7
#2Gillian Gresham (Johns Hopkins University)H-Index: 10
Last. Derek J. Jonker (Ottawa Hospital)H-Index: 25
view all 4 authors...
Abstract Background: KRAS mutations occur in 40% of colorectal cancers (CRCs), affecting the efficacy of agents targeting the epidermal growth factor receptor. However, the effect of KRAS mutation status on the activity of non-epidermal growth factor receptor-targeting chemotherapy has not been fully elucidated. The aim of the present study is to evaluate the effect of KRAS status on the activity of different chemotherapeutic regimens. Patients and Methods: A retrospective chart review of chemot...
1 CitationsSource
#1Elena De MattiaH-Index: 10
#2Jerry PoleselH-Index: 42
Last. Giuseppe ToffoliH-Index: 32
view all 16 authors...
Nuclear receptors act as mediators of cancer-related inflammation and gene expression. They have a regulatory effect on genes encoding proteins related to drug adsorption, distribution, metabolism, and excretion. The aim of the present study was to highlight novel prognostic markers among polymorphisms in genes encoding for nuclear receptor proteins and inflammation-related cytokines in patients treated with a FOLFIRI regimen. This study included two independent cohorts comprising a total of 337...
Source
#1Adrien Labriet (Laval University)H-Index: 2
#2Éric Lévesque (Laval University)H-Index: 24
Last. Chantal Guillemette (Laval University)H-Index: 44
view all 12 authors...
Source
#1A. Vasista (USYD: University of Sydney)H-Index: 1
#2Martin R. Stockler (USYD: University of Sydney)H-Index: 40
Last. Belinda E. Kiely (USYD: University of Sydney)H-Index: 10
view all 20 authors...
1 CitationsSource
#1A.J. Hyde (Ottawa Hospital)
#2Rami Mohamad Nassabein (UdeM: Université de Montréal)
Last. T. Asmis (Ottawa Hospital)H-Index: 8
view all 35 authors...
The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference was held in Halifax, Nova Scotia, 20–22 September 2018. Experts in radiation oncology, medical oncology, surgical oncology, and pathology who are involved in the management of patients with gastrointestinal malignancies participated in presentations and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses multiple topics in the management of pancreatic canc...
Source
#1Elisa Fontana (ICR: Institute of Cancer Research)H-Index: 5
#2G. Nyamundanda (ICR: Institute of Cancer Research)H-Index: 1
Last. Anguraj Sadanandam (ICR: Institute of Cancer Research)H-Index: 23
view all 20 authors...
Abstract Background In CRC, the transit-amplifying (TA) subtype is enriched for tumours sensitive to anti-EGFR agents. At the same time, the presence of TA gene signature in tumours belonging to other subtypes may suggest potential anti-EGFR benefit. Hence, we evaluated the association between the TA signature (presence - class 1; absence - class 2) and outcomes in CRC patients (pts) treated with anti-EGFR therapy. Methods Formalin-fixed, paraffin-embedded samples from a retrospective discovery ...
Source
#1A. de GramontH-Index: 35
#2Julie Henriques (French Institute of Health and Medical Research)H-Index: 3
Last. Thierry AndréH-Index: 59
view all 20 authors...
Abstract Background The AVANT study did not demonstrate disease-free survival (DFS) benefit of the addition of bevacizumab to oxaliplatin-based chemotherapy in stage III resected CC and suggested a potential detrimental effect on overall survival (OS) (A. de Gramont et al. Lancet Oncol. 2012). Here, we present the results of the AVANT study for stage II CC patients. Methods The primary endpoint of AVANT was DFS for stage III disease. As an exploratory measure, AVANT also included high-risk stage...
Source
12345678910